Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II ofL.infantum

Leishmania infantumis known to be associated with visceral leishmaniasis in Iran and canids are natural reservoirs. Control of disease in dogs appears to be one of the most effective approaches for interrupting the domestic cycle of the disease. In search for successful vaccine strategies, we evalua...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2005-05, Vol.23 (28), p.3716
Main Authors: Rafati, Sima, Nakhaee, Alireza, Taheri, Tahere, Taslimi, Yasaman, Darabi, Haideh, Eravan i, Davood, Sanos, Stephanie, Kaye, Paul, Taghikhani, Mohammad, Jamshidi, Shahram, Rad, Mohammad Ali
Format: Article
Language:English
Subjects:
Bone marrow
Deoxyribonucleic acid
Disease control
DNA
Dogs
Immunization
Lymphocytes
Parasites
Parasitic diseases
Protected animals
Vaccines
Vector-borne diseases
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Leishmania infantumis known to be associated with visceral leishmaniasis in Iran and canids are natural reservoirs. Control of disease in dogs appears to be one of the most effective approaches for interrupting the domestic cycle of the disease. In search for successful vaccine strategies, we evaluated the cysteine proteinases (CPs) type I and II using a heterologous prime-boost regime for vaccination against experimental visceral leishmaniasis in dogs. Following vaccination and challenge, dogs were followed for 12 months. Ten dogs vaccinated by prime/boost with DNA/recombinant CPs (in combination with CpG ODN and Montanide 720) remained free of infection in their bone morrow. In contrast, three out of four dogs in the control groups had infection in their bone marrow. The peripheral lymphocytes from protected animals had generally higher proliferation responses to F/T antigen, recombinant CPA (rCPA) and recombinant CPB (rCPB) than controls. During post-challenge period, the difference in stimulation index is significant (p
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2005.02.009